cityslicker99 - It would not make sense to carve out any single opportunity for RVX-208. Because there is a third party standing by to fund the research for HIV, that could end up being a great added bonus for any potential buyer. Whether it's the NIH or any other division it's obviously important to them and may end up saving the US government bags of future expenses.

Apabetalone being so multimodal is both a blessing and a curse. Whatever BP that ends up with this prize is going to make a lot of money for many many years. At this point if a PIII were to start today there could be in excess of 17 years of patent protection. Can anyone give me an example of that ever happening in the past? There is good reason today for there to be a lineup of potential bidders.

tada